Login or sign up
For business

Outlook Therapeutics

4.0· 8 reviews
Average ratingGreat
4.0/ 5

Based on 8 reviews

538%
425%
338%
20%
10%
Ask AI

What reviewers say about Outlook Therapeutics

Generated with AI from 8 reviews on Trustburn · updated 61 days ago

Customers frequently praise the company for offering excellent products, having an easy-to-use website, and providing top-notch customer service, while others report that the products are mediocre, overpriced, or failed to deliver promised results.
What does Outlook Therapeutics do?

Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics.

Are there any complaints about Outlook Therapeutics?

Reviews on file mention that some customers found the products to be overpriced, ineffective, or not worth the price, and noted that customer service was slow, unhelpful, or lacking.

AI-generated from reviews on this page. Verify anything important with the company directly.

Nari Kannan
Reviews 1

Outlook Therapeutics is an average company with mediocre products. Their website is user-friendly but lacks important information. I don't find their products to be effective and they are overpriced. The customer service is also lacking and the response time is slow. Overall, a mediocre experience.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Outlook Therapeutics

Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.

It was founded in 2011 and is headquartered in Cranbury, New Jersey.